<DOC>
	<DOC>NCT01460862</DOC>
	<brief_summary>A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.</brief_summary>
	<brief_title>Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>â‰¥12 years of age with a documented Cystic fibrosis (CF) diagnosis, on Long acting Beta antagonist Inhaled Corticosteroid (LABAICS) at baseline, uncontrolled asthma at baseline. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Omalizumab</keyword>
</DOC>